A phase 2 study of response-guided neoadjuvant sacituzumab govitecan and pembrolizumab (SG/P) in patients with early-stage triple-negative breast cancer: Results from the NeoSTAR trial.
Rachel O. Abelman(Massachusetts General Hospital), Laura M. Spring(Massachusetts General Hospital), Arielle J. Medford(Harvard University), Philip D. Poorvu(Harvard University), Beverly Moy(Global Cancer Institute), Geoffrey Fell(Dana-Farber Cancer Institute), Ana C. Garrido-Castro(Dana-Farber Cancer Institute), Seth A. Wander(Harvard University), Elizabeth A. Mittendorf(Beth Israel Deaconess Medical Center), Amy Comander(Harvard University), Aditya Bardia(UCLA Health), Nadine Tung(Beth Israel Deaconess Medical Center), Leif W. Ellisen(Harvard University), Sara M. Tolaney(Harvard University), Aron S. Rosenstock(Harvard University), Lorenzo Trippa(Harvard University), Filipa Lynce(Institut Claudius Regaud), Shannon McLaughlin(Harvard University), Steven J. Isakoff(Harvard University)
Cited by 11
Related Papers
Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis
|Cell|2014|2.5k
Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
|Science|2013|2.5k
Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment
|Cancer Discovery|2019|1.4k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k